Dashboard

Veru, Inc. (VERU)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

CEO

Mitchell Shuster Steiner

Employees

386

Industry

Specialized Medical Devices

Sector

Healthcare

Headquarters

Miami

Exchange

NASDAQ

Summary Stats

Market Cap

1.01B

Revenue

60.5M

Net Income

-27.5M

EPS

-$0.32

Price-to-Earnings

-39.5

Price-to-Book

7.44

Debt-to-Equity

0.27

News

Analyst Ratings

Price targets projected by 4 analysts

High

$13.00

Average

$8.50

Low

$6.00

Ratings calculated by 4 analysts

Buy

4

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Missed by -$0.03

Actual

-$0.18 -20.0%

Consensus

-0.15

Report Date

Year Ago

-0.04

Year Ago Change %

Down 350%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites